Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders

A pyrazolo and barrier technology, applied to regulate the activity of Eph receptors in cells, stimulate and improve nerve regeneration, and can solve problems such as glial scar reduction, axonal damage, and hyperplasia

Inactive Publication Date: 2009-03-25
NOVARTIS AG
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, experimental inhibition of Eph receptors has shown substantial axon regeneration after injury and suppressed astrogliosis, leading to a marked reduction in glial scarring and making these receptors ideal for spinal cord injury and stroke. therapeutic target for axonal damage and gliosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
  • Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
  • Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0326] In the following preferred embodiments, general expressions may be replaced by corresponding more specific definitions provided in the context to yield more preferred embodiments of the invention.

[0327] Preferred is the use of a compound of formula (I), a tautomer or a pharmaceutically acceptable salt thereof, wherein the Eph receptor-associated (e.g. neurological) injuries and disorders to be treated are dependent on ephrin receptors Neurological disorders or impairments of kinases (eg, EphA4 kinase).

[0328] The present invention particularly relates to the use of the compound of formula (I) or a pharmaceutically acceptable salt thereof and the use of the compound of formula (I) in the treatment of kinase-dependent diseases or for the preparation of pharmaceutical preparations for the treatment of kinase-dependent diseases,

[0329]

[0330] in:

[0331] R 2 is H, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsub...

Embodiment 1

[0375] Example 1: EphA4 mode and mechanism of action

[0376] To distinguish between forward and bidirectional signaling that ephrins are capable of in the context of axon regeneration, lentiviral expression vectors for wild-type and kinase-dead EphA4 were generated and overexpressed in purified astrocytes. Cortical layer neurons form a layer over two astrocyte populations, and axonal outgrowths are analyzed and compared. Biological peptides that have been shown to block the interaction of EphA4 with related ligands and subsequently inhibit receptor activation (Murai, K.K. et al., (2003) Mol Cell Neurosci24(4):p.1000), were tested in star EphA4 inhibitory activity in morphocyte / cortical neuron culture system. Identification of neuronal ligand / ephrin-mediated inhibition of EphA4 by systematically blocking expression of candidate ephrins in neurons using RNA interference to knock down ephrins or using dominant negative ephrin constructs and A coat then forms on wild-type astro...

Embodiment 2

[0378] Example 2: Autophosphorylation and Ligand-Dependent Phosphorylation Assays

[0379] Primary astrocyte cultures were constructed from neonatal mouse cortex and purified to obtain approximately 95-98 pure astrocyte cultures. To detect autophosphorylation, cells were incubated in the presence or absence of pharmacological inhibitors and directly thereafter lysed and subjected to immunoprecipitation and Western blot analysis (eg, Figure 1A shown). For ligand-dependent phosphorylation (such as Figure 1B indicated), the cultures were then serum starved for 36 hours to induce basal receptor phosphorylation, and then treated with a soluble form of the cognate ligand in the presence of a candidate kinase inhibitor or blocking peptide (which was added at various concentrations) in combination with In the absence, stimuli were given for different lengths of time. Cells were lysed and lysates were subjected to EphA4 immunoprecipitation followed by Western blotting to analyze re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to methods of using the compounds of the invention, including pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount.

Description

Background of the invention [0001] Injuries to the adult mammalian central nervous system (CNS) are often characterized by axonal damage, including the failure of several axons to regenerate to their targets, leading to permanent paralysis in individuals with such injuries. There is often no cure for patients suffering from such CNS-related trauma such as spinal cord injury (SCI), which is often accompanied by debilitating clinical conditions like paraplegia or quadriplegia. [0002] Axon regeneration (eg, after injury) is prevented by a number of inhibitory influences in the adult CNS, among them the formation of inhibitory myelin proteins and glial scarring. Considerable progress has been made in identifying molecules associated with myelin inhibition (e.g., Nogo, myelin-associated glycoprotein (MAG), and oligodendrocyte-myelin glycoprotein (OMgp)), Relatively little is known about the glial scar that forms in response to injury. (Grand Pre, T., et al. (2000) Nature, 403 (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61P25/00C07D487/04
CPCA61K31/519C07D487/04A61P25/00A61P43/00
Inventor R·西瓦桑卡兰K·齐默尔曼
Owner NOVARTIS AG